BioDiem could help fight biological weapons
14 February, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and a US army institute will collaborate on research into using antimicrobial BDM-I as a countermeasure for biological weapons including anthrax.
MRCF invests $1.25m in Helmedix to develop autoimmune therapies
14 February, 2013 by Tim DeanEarly-stage biopharma Helmedix has received $1.25m of start-up funding from the Medical Research Commercialisation Fund to develop therapies targeting autoimmune diseases.
Early bird for inaugural Australia China Life Science Summit ending soon
14 February, 2013 by AusBiotechEarly bird registrations will close on 15 February for AusBiotech’s inaugural Australia China Life Science Summit.
Sirtex posts another boost in sales and profit
14 February, 2013 by Tim DeanSirtex (ASX:SRX) has seen sales of SIRSpheres increase by 30.5% and net profit increase by 27.6% to $7.8 million in its half-year results.
CSL hits new heights with 24% increase in profit
13 February, 2013 by Dylan Bushell-EmblingThe market has reacted positively to news that CSL (ASX:CSL) saw a 24% increase in net profit to US$627 million in 1H13 and has completed the restructure of its Australian operations.
Allied receives ISO certification for CardioCel
13 February, 2013 by Tim DeanAllied Healthcare (ASX:AHZ) has received ISO 13485 certification for regenerative therapy CardioCel, bringing it a step closer to European CE Mark approval.
MicroRNA found to inhibit spread of melanoma
12 February, 2013 by Tim DeanA study has shown a microRNA being investigated by MiReven can inhibit the spread of metastatic melanoma, reinforcing its prospect as a potential anticancer agent.
Mesoblast boosts R&D spend on stem cell platform
12 February, 2013 by Dylan Bushell-EmblingThe expansion of Mesoblast’s MPC adult stem cell development programs came at a cost in 1H13, but the company has more than adequate cash reserves to cover the increased burn.
Bioniche details plans for Urocidin
11 February, 2013 by Dylan Bushell-EmblingIn a letter to shareholders, Bioniche’s (ASX:BNC) CEO has laid out some plans for the future of bladder cancer treatment Urocidin following its split with former commercialisation partner Endo Pharmaceuticals.
Phosphagenics solves oxycodone patch design problems and plans for new trial
11 February, 2013 by Tim DeanPhosphagenics (ASX:POH) has solved the crystallisation problems with its oxycodone patch and is aiming to re-enter the clinic by the end of this quarter.
Cellmid options cancer diagnostics tech
11 February, 2013 by Dylan Bushell-EmblingCellmid (ASX:CDY) has secured an option agreement with Japan’s Fujikura covering its midkine cancer diagnostics technology in latex-based tests.
BioDiem testing BDM-I in schistosomiasis
11 February, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and the QIMR are moving to proof-of-concept testing of BioDiem’s antimicrobial in the parasitic worms that cause the major tropical disease schistosomiasis.
Mesoblast up following patents in US and China
07 February, 2013 by Tim DeanMesoblast (ASX:MSB) has made gains on the ASX following an announcement it has secured further patents covering its technology in the US and China.
Free directory listing for Australian biotech and medtech companies
07 February, 2013 by AusBiotechAusBiotech manages two national directories and invites all Australian biotechnology and medical technology companies to list free of charge.
Cynata’s stem cells show promise in treating critical limb ischemia
06 February, 2013 by Tim DeanAn animal trial has shown Cynata’s mesenchymoangioblasts (MCA) cells can help improve blood flow in mice with induced critical limb ischemia.
